Business Context and Reporting Period
This Form 8-K Current Report was filed by ImmunityBio, Inc. on August 15, 2023, regarding events occurring on August 14, 2023. The filing addresses the resolution of litigation claims brought by Sorrento Therapeutics, Inc. ("Sorrento") against ImmunityBio and its subsidiaries.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. It references prior periodic reports (specifically the Form 10-Q for the quarter ended June 30, 2023) for previously disclosed judgments held by the Company's subsidiary NantCell, Inc. and its joint venture NANTibody LLC. As of June 30, 2023, the Company had not recorded any receivables related to these judgments due to uncertainty regarding the amount likely to be recovered.
Material Changes and Litigation Update
On August 14, 2023, the United States Bankruptcy Court for the Southern District of Texas issued an order approving a settlement involving Sorrento's litigation claims. The settlement creates two potential scenarios contingent on Sorrento's ability to raise funds by August 31, 2023:
- Scenario A: If Sorrento raises sufficient funds to pay its debtor in possession lender and unsecured creditors by the deadline, it will pay obligations including judgments held by NantCell and NANTibody. Sorrento would then be free to proceed with pending litigation.
- Scenario B: If Sorrento fails to raise the necessary funds, the judgments will be released, and all litigation claims (including derivative litigation in the Superior Court of Los Angeles) will be dismissed. Additionally, Sorrento will relinquish its interests in NANTibody and forfeit rights to payments from NantCell arising from its antibody exclusive license agreement (PD-L1).
The filing states it remains uncertain which scenario will ultimately be implemented.
Outlook, Risks, and Contingencies
Management highlights significant uncertainties regarding the litigation outcome and the financial stability of Sorrento. The filing includes standard forward-looking statement disclaimers regarding risks such as:
- Ongoing litigation and court process uncertainties.
- Regulatory review processes and FDA responses.
- Ability to secure financing for operations and development.
- Commercialization of product candidates, including N-803 plus BCG.
- Manufacturing scalability and patent protection.
The Company cautions investors not to place undue reliance on forward-looking statements, as they are subject to known and unknown risks.
Investor Verification Checklist
- Verify whether Sorrento Therapeutics, Inc. meets the August 31, 2023, funding deadline to determine the final litigation outcome.
- Review the Form 10-Q for the quarter ended June 30, 2023, for details on previously disclosed judgments and financial exposure.
- Monitor subsequent filings for updates on the status of the NANTibody joint venture and PD-L1 license rights.
- Assess the impact of the litigation resolution on ImmunityBio's balance sheet, specifically regarding potential receivables or asset releases.